ロード中...
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Small cell lung cancer (SCLC) is an aggressive malignancy that accounts for 14% of all lung cancer diagnoses. Despite decades of active research, treatment options for SCLC are limited and resistance to the few Food and Drug Administration (FDA) approved therapies develops rapidly. With no approved...
保存先:
| 出版年: | Transl Lung Cancer Res |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5835589/ https://ncbi.nlm.nih.gov/pubmed/29535912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.02.03 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|